Overview

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Carboplatin
Cyclophosphamide
Epirubicin
Paclitaxel